Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
A closer look at how machine intelligence is helping doctors see cancer in an entirely new light.
Updated
November 28, 2025 4:18 PM
Serratia marcescens colonies on BTB agar medium. PHOTO: UNSPLASH
Artificial intelligence is beginning to change how scientists understand cancer at the cellular level. In a new collaboration, Bio-Techne Corporation, a global life sciences tools provider, and Nucleai, an AI company specializing in spatial biology for precision medicine, have unveiled data from the SECOMBIT clinical trial that could reshape how doctors predict cancer treatment outcomes. The results, presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting, highlight how AI-powered analysis of tumor environments can reveal which patients are more likely to benefit from specific therapies.
Led in collaboration with Professor Paolo Ascierto of the University of Napoli Federico II and Istituto Nazionale Tumori IRCCS Fondazione Pascale, the study explores how spatial biology — the science of mapping where and how cells interact within tissue — can uncover subtle immune behaviors linked to survival in melanoma patients.
Using Bio-Techne’s COMET platform and a 28-plex multiplex immunofluorescence panel, researchers analyzed 42 pre-treatment biopsies from patients with metastatic melanoma, an advanced stage of skin cancer. Nucleai’s multimodal AI platform integrated these imaging results with pathology and clinical data to trace patterns of immune cell interactions inside tumors.
The findings revealed that therapy sequencing significantly influences immune activity and patient outcomes. Patients who received targeted therapy followed by immunotherapy showed stronger immune activation, marked by higher levels of PD-L1+ CD8 T-cells and ICOS+ CD4 T-cells. Those who began with immunotherapy benefited most when PD-1+ CD8 T-cells engaged closely with PD-L1+ CD4 T-cells along the tumor’s invasive edge. Meanwhile, in patients alternating between targeted and immune treatments, beneficial antigen-presenting cell (APC) and T-cell interactions appeared near tumor margins, whereas macrophage activity in the outer tumor environment pointed to poorer prognosis.
“This study exemplifies how our innovative spatial imaging and analysis workflow can be applied broadly to clinical research to ultimately transform clinical decision-making in immuno-oncology”, said Matt McManus, President of the Diagnostics and Spatial Biology Segment at Bio-Techne.
The collaboration between the two companies underscores how AI and high-plex imaging together can help decode complex biological systems. As Avi Veidman, CEO of Nucleai, explained, “Our multimodal spatial operating system enables integration of high-plex imaging, data and clinical information to identify predictive biomarkers in clinical settings. This collaboration shows how precision medicine products can become more accurate, explainable and differentiated when powered by high-plex spatial proteomics – not limited by low-plex or H&E data alone”.
Dr. Ascierto described the SECOMBIT trial as “a milestone in demonstrating the possible predictive power of spatial biomarkers in patients enrolled in a clinical study”.
The study’s broader message is clear: understanding where immune cells are and how they interact inside a tumor could become just as important as knowing what they are. As AI continues to map these microscopic landscapes, oncology may move closer to genuinely personalized treatment — one patient, and one immune network, at a time.
Keep Reading
From pre-orders to market entry, Rokid’s Taiwan campaign reflects how AI hardware is being introduced to consumers today.
Updated
December 17, 2025 1:43 PM
Rokid Glasses, a pair of AR glasses from Rokid. PHOTO: ROKID
Rokid has reached a significant crowdfunding milestone in Taiwan. Its Rokid Glasses campaign surpassed NT$62 million in pre-order funding on zeczec, Taiwan’s creative-oriented crowdfunding platform. The campaign ranked No. 1 across all categories on the platform in 2025 and entered the Top 10 funded campaigns in zeczec’s history, setting new records for AI and XR-related projects.
The campaign launched on October 28 and became one of the platform’s most prominent technology initiatives of the year. According to the company, the outcome followed growing visibility for Rokid Glasses after product showcases in New York, Berlin, Singapore and Paris, positioning the Taiwan campaign within a broader international rollout.
The crowdfunding achievement coincided with Rokid’s official market entry in Taiwan. On December 10, the company debuted Rokid Glasses locally, introducing the product to media, partners and early users in the region. The Taiwan launch mirrored earlier international events and connected the online crowdfunding campaign with a physical market presence.
Rokid Glasses combine augmented reality displays with built-in AI functions, including real-time multilingual translation, live transcription, navigation, object recognition and voice assistance. These capabilities were central to how the product was presented during both the crowdfunding campaign and the Taiwan launch, without framing the project as a traditional consumer electronics release.
The Taiwan campaign builds on Rokid’s prior crowdfunding history. The company previously raised more than US$4 million on Kickstarter, where Rokid Glasses became the highest-funded XR wearable project on the platform. The zeczec campaign extends that track record into one of Asia’s most established consumer electronics markets.
“Taiwan has one of the world's most mature and discerning consumer electronics markets”, said Said Justo Chang, Head of Global Channels at Rokid. “Reaching the top of Taiwan's crowdfunding platform is a great commercial achievement. We are excited to finally introduce Rokid Glasses to Taiwan”.
More broadly, the campaign highlights how crowdfunding platforms continue to function as launch and distribution channels for emerging AI and XR hardware. In Rokid’s case, product rollout, market entry and public participation converged within a single campaign, marking a notable moment for AI-enabled wearables in Taiwan’s technology landscape.